Page 71 - Read Online

Meyer et al. Cancer Drug Resist 2019;2:313-25 I http://dx.doi.org/10.20517/cdr.2019.11 Page 325

chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 2012;26:1517-26.
46. Scuto A, Kirschbaum M, Kowolik C, Kretzner L, Juhasz A, et al. The novel histone deacetylase inhibitor, LBH589, induces expression
of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood 2008;111:5093-100.
47. Annesley CE, Brown P. Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol 2015;6:61-79.
48. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a
Children’s Oncology Group phase I consortium report. J Clin Oncol 2010;28:3623-9.
49. Xu Y, Vakoc CR. Targeting cancer cells with bet bromodomain inhibitors. Cold Spring Harb Perspect Med 2017;7:a026674.
50. Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG. Targeting BET bromodomain proteins in solid tumors. Oncotarget
2016;7:53997-4009.
51. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid
leukaemia. Nature 2011;478:524-8.
52. Braun T, Gardin C. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia
(AML). Expert Opin Investig Drugs 2017;26:803-11.
53. Bardini M, Trentin L, Rizzo F, Vieri M, Savino AM, et al. Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of
MLL-AF4+ Infant ALL. Mol Cancer Ther 2018;17:1705-16.
54. Da Costa D, Agathanggelou A, Perry T, Weston V, Petermann E, et al. BET inhibition as a single or combined therapeutic approach in
primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J 2013;3:e126.
55. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic
leukemia. N Engl J Med 2014;371:1005-15.
56. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute
lymphoblastic leukemia. Blood 2012;120:2843-52.
57. Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, et al. Targeting STAT5 in hematologic malignancies through inhibition of the
bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther 2014;13:1194-205.